N-Gene reports BGP-15 Phase II results

N-Gene (New York, N.Y.) said BGP-15 significantly improved insulin sensitivity, the primary endpoint, in a double-blind, placebo-controlled, Hungarian Phase II study in 42 patients (p>0.01). No change...